TY - JOUR
T1 - Low cancer screening rates among Japanese people with schizophrenia
T2 - A cross-sectional study
AU - Inagaki, Masatoshi
AU - Fujiwara, Masaki
AU - Nakaya, Naoki
AU - Fujimori, Maiko
AU - Higuchi, Yuji
AU - Hayashibara, Chinatsu
AU - So, Ryuhei
AU - Kakeda, Kyoko
AU - Kodama, Masafumi
AU - Uchitomi, Yosuke
AU - Yamada, Norihito
N1 - Funding Information:
Dr. Inagaki reports personal fees from Pfizer, Mochida, Shionogi, Sumitomo Dainippon, Daiichi-Sankyo, Meiji Seika, Takeda, Nippon Hyoron-Sha, Nanzando, Seiwa Shoten, Igaku-shoin, and Technomics outside the submitted work. Dr. Fujiwara reports personal fees from Mochida, Sentan Igaku-Sha, Igaku-shoin, and Seiwa Shoten outside the submitted work. Dr. Fujimori reports personal fees from Mochida, Igaku-Shoin, Chugai-Igakusha, Nankodo, and Kongo-Shuppan outside the submitted work. Dr. So reports personal fees from Kagakuhy-ronsha, Medical Review, and Otsuka outside the submitted work. Dr. Kakeda reports personal fees from Mochida outside the submitted work. Dr. Kodama reports personal fees from Janssen, Otsuka, MSD, Eisai, Yoshitomiyakuhin, and Eli Lilly outside the submitted work. Dr. Uchitomi reports personal fees from Mochida, Eisai and other fees from QOL Co., outside the submitted work; annual fees under JPY 500,000 from companies are not disclosed. Dr. Yamada reports grants from Daiichi Sankyo, Eisai, Otsuka, Astellas, MSD, and Pfizer, and personal fees from UCB Japan, Tsumura, Sumitomo Dainippon, Daiichi-Sankyo, MSD, Pfizer, Eisai, Meiji Seika, and Mochida outside the submitted work. The remaining authors declare no conflicts of interest.
Funding Information:
This work was supported by the Okayama Health Foundation, Novartis Pharma Research Grants, Research for Promotion of Cancer Control Programs (H26-political-general-002), and JSPS KAKENHI, grant number JP17K09112.
Publisher Copyright:
© 2018 Tohoku University Medical Press.
PY - 2018/3
Y1 - 2018/3
N2 - Health care disparities among people with schizophrenia is a global concern. Our previous study revealed cancer screening rates in Japanese people with schizophrenia lower than rates of approximately 40% of the general population. However, that study was based on self-reports, which can be inaccurate, and rates did not differentiate the types of cancer screening provider (i.e., municipal screening, collective opportunistic screening, and individual opportunistic screening). This study aimed to investigate records-based cancer screening rates, focusing on participation rates of people with schizophrenia who are subject to municipal cancer screening programs. We conducted a cross-sectional study at a psychiatric hospital outpatient clinic from September to November 2016. We randomly extracted 420 potential participants from among 680 eligible patients and asked them to participate. We then selected subgroups of participants living in Okayama city who were enrolled in the National Health Insurance or Public Assistance systems and were subject to colorectal, gastric, lung, breast, or cervical cancer screening provided by Okayama city (n = 97, 96, 97, 42, and 64, respectively). Participation in cancer screenings was assessed based on local government records. Municipal cancer screening rates were as follows: 13.4% (95% confidence interval: 6.6%-20.2%) for colorectal, 7.3% (2.1%-12.5%) for gastric, 16.5% (9.1%-23.9%) for lung, 21.4% (9.0%-33.8%) for breast, and 14.1% (5.6%-22.6%) for cervical cancers. The findings demonstrated extremely low cancer screening rates among people with schizophrenia subject to municipal cancer screenings in Japan. A strategy to promote municipal cancer screening for people with schizophrenia is needed.
AB - Health care disparities among people with schizophrenia is a global concern. Our previous study revealed cancer screening rates in Japanese people with schizophrenia lower than rates of approximately 40% of the general population. However, that study was based on self-reports, which can be inaccurate, and rates did not differentiate the types of cancer screening provider (i.e., municipal screening, collective opportunistic screening, and individual opportunistic screening). This study aimed to investigate records-based cancer screening rates, focusing on participation rates of people with schizophrenia who are subject to municipal cancer screening programs. We conducted a cross-sectional study at a psychiatric hospital outpatient clinic from September to November 2016. We randomly extracted 420 potential participants from among 680 eligible patients and asked them to participate. We then selected subgroups of participants living in Okayama city who were enrolled in the National Health Insurance or Public Assistance systems and were subject to colorectal, gastric, lung, breast, or cervical cancer screening provided by Okayama city (n = 97, 96, 97, 42, and 64, respectively). Participation in cancer screenings was assessed based on local government records. Municipal cancer screening rates were as follows: 13.4% (95% confidence interval: 6.6%-20.2%) for colorectal, 7.3% (2.1%-12.5%) for gastric, 16.5% (9.1%-23.9%) for lung, 21.4% (9.0%-33.8%) for breast, and 14.1% (5.6%-22.6%) for cervical cancers. The findings demonstrated extremely low cancer screening rates among people with schizophrenia subject to municipal cancer screenings in Japan. A strategy to promote municipal cancer screening for people with schizophrenia is needed.
KW - Cancer screening
KW - Healthcare disparities
KW - Mental disorder
KW - Preventive health services
KW - Schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=85045197621&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85045197621&partnerID=8YFLogxK
U2 - 10.1620/tjem.244.209
DO - 10.1620/tjem.244.209
M3 - Article
C2 - 29540627
AN - SCOPUS:85045197621
SN - 0040-8727
VL - 244
SP - 209
EP - 218
JO - Tohoku Journal of Experimental Medicine
JF - Tohoku Journal of Experimental Medicine
IS - 3
ER -